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Copyright © 2015 Carmen Andréa F. Lopes et al.This is an open access article distributed under theCreativeCommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in anymedium, provided the originalwork is properly cited.
HIV related mutations can be associated with decreased susceptibility to antiretrovirals and treatment failures. There is scarce
information about HIV mutations in persons failing HIV treatment in North of Brazil. Our aim was to evaluate evolution of
HIV subtypes and mutations patterns related to antiretroviral therapy in this region. We investigated HIV resistance profile in
adults failing antiretroviral regimen in Northern Brazil from January, 2004, through December, 2013. Genotype data was evaluated
through Stanford University algorithm.There were 377 genotypes from different individuals to evaluate. Resistance mutations were
similar to worldwide reports and related to antiretroviral exposure. Most prevalent mutations in the reverse transcriptase gene
were M184V (80.1%) and K130N (40.6%).Thymidine associated mutations were more frequent in multiexperienced patients. Most
common protease mutations were M46I, V82A, I54V, L90M, I84V, M46L, and L76V. Subtype B was the most prevalent (90.7%).
There were differences between subtypes B and non-B mutations. We documented for the first time subtypes and patterns of HIV
associated mutations in Northern Brazil. A1 subtype was identified for the first time in this area. Depending on drug regimen and
how experienced the patient is, an empirical switch of a failing antiretroviral treatment could be a reasonable option.
1. Introduction
The use of highly active antiretroviral therapy (HAART) has
dramatically changed the natural course of HIV infection in
little more than 30 years of its existence [1, 2]. Although
potentially fatal, HIV infection is now considered a chronic
and treatable infection [3–6]. Nevertheless, the success of the
treatment is closely related to the continuous use of drugs in
order to assure persistent plasma viral load (VL) suppression
[7, 8].
As HAART cannot eradicate HIV infection, drugs should
be friendly to the patient, easy to take, and with reduced or
ideally without side effects [9].Therefore, treatment success is
directly related to adherence to treatment without viral repli-
cation in plasma [10]. Incomplete HAART viral suppression
(due to adherence problems or low potency of the combined
medications) is related to the development of viral failure [11].
The continuous replication of HIV under the selective pres-
sure of antiretrovirals (ARVs) will eventually lead to the selec-
tion ofHIVmutations associatedwith resistance [12].The accu-
mulation of mutations further compromises HIV treatment
and limits future options if cross-resistance to other ARVs
is developed [13, 14]. Therefore, early detection of viral fail-
ure is extremely important. The persistence or rebound to
detectable levels of HIV in plasma could be an early sign of
low adherence or the existence of resistance [15]. The longer
the patient is exposed to such treatment, the higher will be the
chance to accumulate mutations and develop resistance [16].
An important tool to identify HIV drug resistance muta-
tions is the genotyping test [14]. Although specific patterns
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of HIV resistance are well established according to the ARV
used, they can vary depending on the HIV genetic form
(subtype or circulating recombinant form) and drugs used
[17, 18].
There are no more than a few Brazilian reports on
acquired drug resistance [19–22], transmitted drug resistance,
and characterization of the HIV-1 genetic variability [23–
27]. HIV-1 subtype B is prevalent throughout the country
[19–22], whereas subtypes C and F and their recombinants
are relevant in the South and Southeast regions, respectively
[28–32]. However, there is scarce data on the circulation of
subtypes in the North region of Brazil [33, 34]. The objective
of this study was to evaluate the emergence of HIV drug
resistance, the possibility of an empirical antiretroviral switch
(while waiting for genotyping result), and patterns associated
with circulating subtypes and ARVs utilized in a population
in Pará, one of the largest states in the North region of Brazil.
2. Population and Methods
This was a cross-sectional retrospective study that evaluated
HIV genotyping results from individuals with virologic
failure (VL greater than 5,000 copies/mL until 2007, and
greater than 2,000 copies/mL after 2008), followed up at four
public specialized HIV clinics in Belém city, the capital of
Pará state, themost populous state of theNorth of Brazil. Data
was collected from January 2004 through December 2013,
from the standardized Brazilian HIV genotyping national net-
work of the Ministry of Health (RENAGENO), (http://www
.aids.gov.br/pagina/2010/sistema-e-informacao-para-rede-de-
genotipagem-sisgeno).The HIV genotyping assay conducted
was the ViroSeq HIV-1 Genotype System from Celera
Diagnostics (Alameda, CA, USA) in the period from 2004
to 2008 and the TRUGENE System (Siemens, Munich,
Germany) from 2009 to 2013. Patients above 18 years of age
were enrolled in the study. Only the first available exam was
included in those with more than one HIV genotyping text
performed.
From the total 464 exams retrieved, 87 were excluded
for the following reasons: 19 were conducted in non-
RENAGENO laboratories, 12 were from patients under 18
years old, 49were duplicated, and seven presented incomplete
or unreadable results.Therefore, 377 cases remained available
for evaluation in the study.
Mutations were described according to the Stanford Uni-
versity HIV Drug Resistance Database (http://hivdb.stanford
.edu/). Genotypic resistance was defined as the presence of
one or more resistance-related mutations as specified by this
database and was further classified according to the ARV
class to which they confer reduced susceptibility: nucleo-
side reverse transcriptase inhibitors (NRTIs), nonnucleo-
side reverse transcriptase inhibitors (NNRTIs), and protease
inhibitors (PIs).
Clinical cases were classified according to the number of
regimen failures as follows: first failure, second failure (two
treatments), andmultifailure (when three ormore treatments
were experimented prior to genotyping). We also analyzed
the association between the mutations observed and the
associated HIV-1 subtype (B versus non-B).
Table 1: Characteristics of patients failing ARV.
Characteristics Total (377)
Age in years




Mean (range) 199.93 (±173,36)
HIV RNA level (log
10
copies/mL)
Mean (range) 5.005 (±5,509)
Number of therapeutic failures
First treatment 91 (24.2%)
Second treatment 85 (22.5%)
Multiexperienced 201 (53.3%)
ARVs before genotyping
NRTIs + NNRTIs 177 (46.9%)
NRTIs + PI/r 131 (34.8%)
NRTIs + PI 53 (14.1%)
NRTIs + NNRTIs + PI/r 12 (3.2%)
NRTIs + double-boosted PI 2 (0.5%)
NRTIs only 2 (0.5%)
Antiretrovirals, ARV; nucleoside reverse transcriptase inhibitors, NRTIs;
nonnucleoside reverse transcriptase inhibitors, NNRTIs; protease inhibitors,
PI; boosted protease inhibitors, PI/r.
The sample size was estimated with the statistical package
Winpepi (v.11.37). A prevalence of 82% for subtype B was
considered according toCavalcante et al. [20], with a standard
error of 4% and a confidence level of 95%, estimating a
minimum size of 355 genotypes for the study. Qualitative
variables were evaluated by the Pearson’s Chi-square Test,
Fisher’s Exact Test, or Monte Carlo Exact Significance (when
the other tests were not appropriate to be used), and the level
of significance was established to 0.05. Data were analyzed in
SPSS v.18.0.
The protocol of the study was elaborated according to the
resolution number 466 of December 12, 2012, from Conselho
Nacional de Saúde (National Health Council) for scientific
research in humans and was approved by Comitê de Ética em
Pesquisa do Núcleo de Medicina Tropical de Belém do Pará
(Ethics Committee in Research of the Nucleus of Tropical
Medicine of Belém, Pará) under the number 212.966.
3. Results
Overall, 377 genotyping tests were analyzed. The mean age
of the patients was 40.7 years (±9.43) and most samples were
from men (𝑛 = 250; 66.3%). The main characteristics of the
population in which the tests have been performed can be
seen in Table 1. There were 332 (88.1%), 247 (65.5%), and
164 (43.5%) mutations associated with resistance to NRTIs,
NNRTIs, and PIs, respectively. In 18 cases (4.8%) nomutation
associated with resistance was identified.























10 20 30 40 50 60 70 80 900
(%)
(a)


























































10 20 30 40 50 60 700
(%)
(d)
Figure 1: Prevalence of resistancemutations to theNRTIs (a) andNNRTIs (b).Majormutations (c) and accessorymutations related resistance
to the PI (d).𝑁 = 377.
Considering HIV subtype, the vast majority of cases were
B (𝑛 = 301; 90.7%), and amongst the non-B, F1 was the most
frequent (19 cases; 5.7%). We were able to identify subtype
A1 (first case in that region) in the sample. There was no
significant difference in the proportion of failures between
HIV subtypes during the years studied.
All patients were taking NRTIs at the time the genotyping
test was done (Table 1). The most prevalent mutations related
to NRTIs were M184V (80.1%), followed by M41L (31.8%),
T215Y (30.2%), D67N (25.5%), K70R (24.4%), T215F (18.3%),
L210W (15.1%), and V118I (15.1%) (Figure 1(a)). Taking into
account multiple mutations together, the thymidine analog
mutations (TAM) pathway 1 (including M41L, L210W, and
T215Y) was selected in 40.8% of the patients, whereas TAM-
2 (including D67N, K70R, T215F, and 58 K219Q/E) was
present in 42.2%. The M41L, D67N, V118I, L210W, K219Q,
and T69D mutations were more prevalent in experienced
patients. The higher the number of ARV regimens already
used, the higher the chance of having multiple mutations
associated with resistance to zidovudine (ZDV), stavudine
(d4T), and tenofovir (TDF) (𝑝 = 0.011, 0.010, and <0.001,
resp.).
Half of the patients (50.1%) were using NNRTIs at the
time of genotyping and most of those (83.6%) were on
efavirenz (EFV) (Table 1). The K103N mutation (40.6%) and
P225H mutation (10.6%) were the most prevalent mutations
(Figure 1(b)). At the time of the analysis, K103N (𝑝 < 0.001)
and P225H (𝑝 = 0.037) were associated with the first regimen
failure, while G190S (𝑝 = 0.013) and M230L (𝑝 = 0.008)
were associated with the second failure. EFV and nevirapine
(NVP) had a higher prevalence of resistance in the first failure
(𝑝 < 0.001 for both).
Approximately half of the patients (52.6%) were taking
PIs at the moment of the genotyping test (Table 1). The most
prevalent major PI mutations were as follows: M46I (21%),
V82A (17%), I54V (16.4%), L90M (13.5%), I50L (8.2%), I84V
(5.8%), D30N 22 (5.8%), and M46L (5%) (Figure 1(c)). With
respect to accessory or secondary mutations, the most fre-
quent were L63P (60.7%), M36I (41.1%), I93L (40.1%), I62V
(39%), V77I (35.8%), A71V (24.9%), and L10I (24.7%) (Fig-
ure 1(d)). Again, the number of ARV regimens prescribed
was positively correlated with the chance of having multiple
mutations associated with resistance. In the experienced
subgroup, at least seven major (M46I, V82A, I54V, L90M,
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I84V, M46L, and L76V) and 15 accessory mutations (I62V,
A71V, L10I, L10V, K20R, L33F, Q58E, K20T, L10F, T74S, F53L,
K43T, G73S, I85V, and A71I) developed and were associated
with resistance (𝑝 < 0.05).
There were some differences regarding the selection of
mutations in relation to HIV subtypes (B versus non-B).
In the reverse transcriptase gene, the T215F mutation was
significantly more selected in non-B subtypes (𝑝 = 0.023).
As for the protease gene, only one major mutation, L76V, was
selected more frequently in non-B subtypes (𝑝 = 0.041). In
contrast, several secondary mutations were found to differ
between B and non-B subtypes: L63P (𝑝 < 0.001) and A71T
(𝑝 = 0.021) were higher in subtype B, and M36I (𝑝 < 0.001),
K20R (𝑝 < 0.001), L10V (𝑝 = 0.004), L89M (𝑝 < 0.001), and
F53L (𝑝 = 0.011) were higher in non-B subtypes.
4. Discussion
In the present study we tried to identify, for the first time
with a more consistent data, the patterns of HIV resistance
according to ARVs used and HIV subtypes in an unexplored
geographical region from the North of Brazil. Belém of Pará
ranks the eighth Brazilian capital with the highest number
of AIDS cases [35]. Although the RENAGENO has started
in 2001 and the inclusion of the state of Pará only took
place in 2004, with restrictions on the number of tests in
the first years, we think our study is representative because
it concentrated on 91% of the total genotyping analyses
performed in the state.
The resistance-associated mutations profile showed a
high prevalence of M184V, TAMs, and K103N in RT. This
is in agreement with studies correlating them with the
expanded access to HAART in the last decade [8, 36, 37].
Resistance to NRTIs in multifailed patients was related to
the presence of the TAMs M41L, D67N, L210W, and K219Q.
The accumulation of TAMs, generally over 4, and the TAM-
1 mutational pathway confers cross-resistance to nucleoside
analogues, including TDF, which may prevent NRTI usage
in the composition of subsequent therapeutic rescue regimen
[14, 38].
First-generation NNRTIs have low genetic barrier
towards drug resistance and for cross resistance in the class
[14].These drugs were part of HAART in 50.1% of the sample
(Table 1). The high prevalence of the K103N (40.6%) and
the P225H (10.6%) mutations detected was associated with
high-level resistance to efavirenz and nevirapine in the first
antiretroviral treatment, as was expected [39]. Although
our patients did not use the second-generation NNRTI,
etravirine (ETR), cross-resistance to this drug was significant
in regimens of second failure (31.9%), associated with G190S
and M230L mutations. Mutations associated with resistance
to ETR have different impact and are usually analyzed by
a weighted score of mutations. M230L alone produces
moderate resistance to ETR, while G190S requires at least
another mutation of equal weight to establish resistance
[40]. Fortunately, the prevalence of these mutations was low
(<5%), which is in accordance with other studies [41, 42].
Ritonavir-boosted protease inhibitors (PIs) have high
genetic barrier towards resistance, requiring a larger number
of mutations to present resistance [14, 38]. The group studied
here has little experience with PIs and this fact may explain
the low prevalence of major PI mutations observed in
initial failures. On the other hand, in multifailed individuals,
seven major PI mutations associated with resistance were
documented: M46I, V82A, I54V, L90M, I84V, M46L, and
L76V. Despite the reduced exposure of the studied patients to
atazanavir (ATV/r; 21.9%), a large proportion of multifailed
patients (56%) displayed genotypic resistance to that drug.
Likely, amprenavir/ritonavir (APV/r) was used prior to the
genotyping test in only two cases (1%), both multifailed
patients, and is not likely to explain the high rate of resistance
found (48%) to this drug. Previous PI-based treatments
might have contributed to the emergence of PI major muta-
tions M46I, V82A, L90M, I84V, M46L, and L76V, associated
with resistance to APV/r.
The selection of the I84V mutation is common to all
PIs, including those with the highest genetic barrier, DRV/r
and TPV/r [38]. Despite being multifailed patients, DRV/r
would be the best PI to rescue HIV treatment, as only
10.9% of the samples demonstrated resistance to the drug.
The same was not true with TPV/r, which had documented
resistance in 22.1% of the samples.This finding is somehow in
accordance with other reports [43]. We think, however, that
the Q58Emutation, together with other accessory mutations,
L10V, L33F, and K43T, may have contributed to the higher
prevalence of TPV/r resistance in relation to DRV/r observed
in our study.
HIV-1 subtype B is reported as the predominant viral
genetic form in the State of Pará [33], and we corroborate
those reports in our study, with a high prevalence of this
subtype (90.7%). Indeed, a temporal distribution analysis of B
and non-B subtypes during the ten years of the study failed to
show significant variation (𝑝 = 0.280), providing evidence for
a stabilized HIV epidemic in terms of diversity in the state of
Pará. However, our study reports the presence of subtype A1
for the first time in the state. This subtype is highly prevalent
in severalAfrican countries anddisseminatedworldwide [44]
but with anecdotal reports in Southeastern Brazil [19]. Non-
B subtypes as F1 (5 cases; 1.5%) and C (2 cases; 0.6%) are
congruent to the low prevalence reported previously [33].
In our study, L76V PI-associated mutation was the only
one that differed significantly in prevalence between B and
non-B subtypes, being more frequent in the latter. Specific
accessory PI mutations were associated with B and non-B
subtypes. L63P and A71T were associated with subtype B,
whereas L10V, K20R, M36I, F53L, and L89M were linked to
non-B subtypes. Our results are in agreement with previous
studies conducted in Brazil that studied the association of
PI related polymorphisms with specific HIV genetic forms
[19, 22]. There are some data suggesting that primary, com-
pensatory, and polymorphic mutations might intervene with
the response and durability of an antiretroviral regimen.
Nevertheless, clinical trials are still needed to better define
this issue [45–47].
In summary, we found that the prevalence of mutations
in the TR of HIV-1 was similar to data already reported.
There was a relevant emergence of M184V and TAMs, related
to NRTIs, and of K103N, related to the NNRTIs. In PR,
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mutations M46I/L, I54V, L76V, V82A, I84V, and L90M
were associated with PI/r resistance in multifailed patients.
The accumulation of NRTIs and PI/r related mutations was
associated with resistance in multifailure, confirming the
hypothesis that failure to treatment results from the cumu-
lative acquisition of resistance mutations. HIV-1 subtype B
was the most prevalent in the state of Pará, and over the
decade studied there was evidence of stabilization of this
subtype in the state. Based on our findings, we conclude that
the mutation patterns of HIV in Pará state were similar to
other places worldwide. Also, it is quite reasonable to suppose
that, in some situations, depending on drug regimen and how
experienced the patient is, an empirical switch of a failing
antiretroviral treatment could be a reasonable option while
waiting for genotyping result.
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[32] T. Gräf and A. R. Pinto, “The increasing prevalence of HIV-
1 subtype C in Southern Brazil and its dispersion through the
continent,” Virology, vol. 435, no. 1, pp. 170–178, 2013.
[33] L. F. A. Machado, M. O. G. Ishak, A. C. R. Vallinoto et al.,
“Molecular epidemiology of HIV type 1 in northern Brazil:
identification of subtypes C and D and the introduction of
CRF02 AG in the Amazon region of Brazil,”AIDS Research and
Human Retroviruses, vol. 25, no. 10, pp. 961–966, 2009.
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Amazônica de Saúde, vol. 3, no. 2, pp. 11–16, 2012.
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